title: Willingness to pay for praziquantel treatment in a hyperendemic community of Ogun State, Nigeria.
abstract: BACKGROUND
  Schistosomiasis is highly endemic in Nigeria. However, very little is known about the usage and social marketing of praziquantel in the control of schistosomiasis in endemic communities and on the persons willingness to pay for the drug to support its extensive use and thus aid control efforts in Nigeria.
  
  
  OBJECTIVE
  The study examined the willingness of people in a hyperendemic community, to pay for treatment with praziquantel before and after provision of the drug, with a view to assess the feasibility of achieving widespread coverage.
  
  
  METHODS
  Data were collected through focus group discussions among household heads and other adult family members and through the use of a questionnaire to survey household heads in Imala-Odo, a community hyperendemic for schistosomiasis, in southwest Nigeria. The main outcome measure was the respondents' willingness to pay for schistosomiasis treatment.
  
  
  RESULTS
  The results showed that in contrast to the 92.3% of respondents who expressed willingness to buy the drug in the preintervention study, only 46.5% actually purchased the drug during intervention for the treatment of their infected household members. The respondents' level of education, occupation, and income influenced their willingness to pay (P<.05). Statistical tests showed that those willing to pay for treatment had a higher income score than those unwilling to do so. Most respondents preferred their community head and reliable persons chosen by the community as convenient outlets for drug distribution. The number of household members respondents were willing to treat increased from 4 to 6 at N320.00 (US $2.52) in the preintervention and postintervention phases, respectively. Gender factor was found to influence the respondents' perceived average treatment cost; the females wanted N300.00 (US $2.36) against N100.00 (US $0.79) among the males.
  
  
  CONCLUSIONS
  Efforts need to be made and sustained to ensure that all families can afford to praziquantel drug to achieve the ultimate goal of controlling the infection in endemic communities of Nigeria.
authors.affiliation: Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria. oakadeneye@yahoo.co.uk
authors.forename: A K
authors.initials: AK
authors.lastname: Adeneye
authors.forename: M A
authors.initials: MA
authors.lastname: Mafe
authors.forename: B
authors.initials: B
authors.lastname: Appelt
authors.forename: E T
authors.initials: ET
authors.lastname: Idowu
authors.forename: D O
authors.initials: DO
authors.lastname: Akande
mesh_terms: D000293:Adolescent; D000328:Adult; D000871:Anthelmintics / Q000191:economics* / Q000627:therapeutic use; D019353:Endemic Diseases / Q000191:economics*; D005240:Feasibility Studies; D005252:Fees, Pharmaceutical; D005260:Female; D005382:Financing, Personal; D015438:Health Behavior; D019538:Health Care Surveys; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D008297:Male; D008875:Middle Aged; D009549:Nigeria / Q000453:epidemiology; D010342:Patient Acceptance of Health Care; D011223:Praziquantel / Q000191:economics* / Q000627:therapeutic use; D012552:Schistosomiasis / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D012959:Socioeconomic Factors; D011795:Surveys and Questionnaires
chemical_list: D000871:Anthelmintics; D011223:Praziquantel